A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
about
uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.Characterization and function of human Ly-6/uPAR molecules.CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissueAscites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.Role of urokinase receptor in tumor progression and development.Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences.Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.Challenges for drug discovery - a case study of urokinase receptor inhibitionUrokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers.Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
P2860
Q24642555-D9B5900D-D1BD-4DD5-B3CC-271C47BFABACQ30311208-803C4FA0-8EA3-43E2-B131-C7B3A814AA7BQ31038443-5DFF1248-27E3-4F69-8FF7-872D824D3515Q31506532-011F6B5C-85E8-4F9B-9695-2E49BE49DBCFQ33538432-E7455962-71C3-4F08-A3E7-9FD409A731DAQ34165118-95151B92-E7FF-413C-B5AA-07021DA70294Q34314038-5A0C1C32-EA87-4778-AA5B-50DFF6753B86Q35606333-334B9BCD-AAF1-4E91-A079-9C9D544E9124Q35764327-98123A7D-BAD0-4023-8D74-AADC7BC02EEBQ36616741-570E66D0-EDE5-425C-9A12-34EC73EF96FCQ36619276-5FDF2C42-43BF-4DEF-B250-8506AA611DD1Q36619635-69E4FDF5-4579-4475-A18B-0B31CDF98C42Q36840119-C7C5C805-28D3-45CE-8EA5-682C6B79E975Q36997616-FDD277BD-8F8F-4B2E-ADA9-995AECFDCFF4Q37154428-9F13A2C0-B313-41FF-8BC9-8CF19489EBA6Q38189275-36E26A7B-8EDC-414C-8E21-701622A29DD5Q39515171-55EFF6EF-69A6-44D5-ABCE-CD5C0B22EAFEQ40444813-1E29C28F-B437-4AA0-AD41-E2F0FA14814FQ40475372-BFBB929C-676A-418D-BCC2-144757D4A919Q40784517-4488035D-FA39-40D2-8E9A-B9773A0538E7Q40942602-50A7A9F4-8AE3-4B3C-AA34-AFDA9229377AQ41559739-DD0946E9-D3CD-48E5-829E-FE0C998F8B33Q41908264-D534D53C-AD59-48F6-9FE9-1BB0DAE55B22Q43000092-79F19A17-82F7-45E8-BF58-8633E8D3AAF7Q47251534-ECD4EA6C-E1A6-46EF-8C04-BCFC3656F00BQ47892317-C8CB9A27-AEE9-4E1B-9A58-C65F538E8DBFQ47896134-4971BC62-1E36-4D61-B098-7F18ED214E5C
P2860
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@ast
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@en
type
label
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@ast
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@en
prefLabel
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@ast
A ligand-free, soluble urokina ...... patients with ovarian cancer.
@en
P2093
P2860
P356
P1476
A ligand-free, soluble urokina ...... m patients with ovarian cancer
@en
P2093
Høyer-Hansen G
Nicoletti MI
Pedersen N
P2860
P304
P356
10.1172/JCI116817
P407
P577
1993-11-01T00:00:00Z